KELOWNA, British Columbia, August 03, 2021 (GLOBE NEWSWIRE) – Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID), an international medical company focused on creating and delivering health solutions to solve today’s medical mental health challenges is pleased to announce that it has launched its second commercial shipment of cannabidiol (“CBD” ) (containing less than 0.3% THC) from Colombia to the United States, specifically to the state of Colorado.
Allied has demonstrated its supply chain of producing in Colombia and exporting wholesale CBD products to international markets. This American commercial cargo was produced from seed in Colombia at the Allied commercial production site, approved for export by the Colombian Ministries of Justice, Health and Agriculture, and transported to the United States. United. It must be validated by the customs and border services of the United States of America for import approval. If approved for import, it will be transported to arrive at the CBD manufacturer in the United States located in the state of Colorado. Allied’s supply chain ranges from seeds in Colombia to retail CBD products on the shelves in the United States, which we believe to be the largest market in the world.
“In our opinion, if approved, launching more than one shipment to the United States has demonstrated Allied’s supply chain from a seed grown in Colombia to the market in the United States. We think of Colorado as a unique state in that it has large national consumer packaged products companies that manufacture there, ”said Calum Hughes, CEO of Allied.
About Allied Corp. – https://allied.health/
Allied Corp. is an international healthcare company whose mission is to solve today’s medical problems by researching, creating and producing targeted healthcare solutions. Allied Corp. uses an evidence-based scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative development of herbal and fungal therapeutics.
Forward-looking statements: This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or “forward-looking statements” made in accordance with the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, ” forward-looking information ”). Forward-looking information may relate to the future prospects of the Company and anticipated events, plans or results, and may include information relating to the objectives, goals, strategies, future income or performance and capital expenditures of the Company, as well as other information that is not historical information. Forward-looking information can often be identified by the use of terms such as “believe”, “anticipate”, “plan”, “expect”, “pending”, “in progress”, “intend” , “Estimate”, “project”, “” may “,” will “,” should “,” would “,” could “,” could “, the negative aspects thereof, their variations and similar expressions. forward-looking statements contained in this press release are based on the opinions, estimates and assumptions of the Company in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as of other factors that management currently considers appropriate and reasonable under the circumstances Forward-looking statements in this press release include the following: that Allied is taking advantage of the conditions of its cultivation operation in Colombia and its future Kelowna site to so to sustain its research and development efforts; that Allied is making significant progress to position itself as a leader in medical cannabis, that Allied intends to file a series of trademark and other intellectual property protection filings , as part of the Company’s Intellectual Property and Pharmaceutical Development (IP&PD) strategy, statements regarding the joint development, manufacture and introduction of TACTICAL RELIEF ™ brand products, and the use of TACTICAL RELIEF ™ brand products. offer of convertible notes.
There can be no assurance that the opinions, estimates and underlying assumptions will prove to be correct. The risk factors that could cause actual results to differ materially from the forward-looking information contained in this press release include: the Company’s exposure to legal and regulatory risks; the effect of the legalization of adult cannabis in Canada and Colombia on the medical cannabis industry is unknown and could significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosage and social acceptance of cannabis are not currently expected; that unfavorable changes or developments affecting the Company’s main or planned facilities may have an unfavorable effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as expected or that the Company may not be able to succeed in this market; risks related to the completion of greenhouse construction in Colombia, risks related to market competition; risks associated with the proposed adult cannabis industry and market in Canada and Colombia, including the Company’s ability to enter or compete in these markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks associated with the Company’s current or proposed international operations; risks associated with future strategic alliances with third parties or the expansion of existing relationships with third parties; that the Company may not be able to identify and successfully execute future acquisitions or divestitures or to successfully manage the impacts of such transactions on its operations; the risks inherent in operating a farming business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant disruptions in the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may not be able to transport its cannabis products to patients in a safe and efficient manner; risks relating to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s dependence on pharmaceutical distributors; that the Company, or more generally the cannabis industry, may receive unfavorable publicity or be the subject of a negative perception by consumers or investors; that certain events or developments in the cannabis industry more generally may have an impact on the reputation of the Company or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage with respect to the risks it faces, that the premiums for such insurance may not continue to be commercially justifiable, or that it may there are coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become responsible for the fraudulent or illegal activity of its employees, subcontractors, consultants and others; that the Company may suffer breaches of security in its facilities or losses as a result of the theft of its products; risks related to the Company’s IT systems; that the Company may not be able to support the growth and development of its sales; that the Company may not be able to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to obtain adequate or reliable sources of financing; risks related or associated with the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks associated with fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater than expected tax obligations; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses to third parties; that the Company may be the subject of allegations that it or its licensors are infringing the intellectual property rights of others; that the Company may not take full advantage of the clinical trials or studies in which it participates; that the Company may not take full advantage of its licenses if the licensed material has less market appeal than expected and the licenses may not be cost effective; as well as any other risk that may be described in more detail in and the risk factors discussed in the Company’s continuous information, including the sections Management report and analysis in its quarterly reports on Form 10-Q, annual reports on Form 10-K and current reports on Form 8-K filed under the company profile on www.sec.gov.
Although management has attempted to identify significant risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors currently unknown to the Company. Company or which, in the Company’s opinion, are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Therefore, readers and viewers should not place undue reliance on forward-looking information, which is only valid as of the date of its publication. The forward-looking information contained in this press release represents the Company’s expectations as of the date of this press release or as of the date indicated, regardless of the delivery time of the presentation. The Company disclaims any intention, obligation or commitment to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.